Nuvalent (NUVL) Stock Forecast, Price Target & Predictions
NUVL Stock Forecast
Nuvalent stock forecast is as follows: an average price target of $114.80 (represents a 46.65% upside from NUVL’s last price of $78.28) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
NUVL Price Target
The average price target for Nuvalent (NUVL) is $114.80 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $100.00. This represents a potential 46.65% upside from NUVL's last price of $78.28.
NUVL Analyst Ratings
According to 10 Wall Street analysts, Nuvalent's rating consensus is 'Buy'. The analyst rating breakdown for NUVL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nuvalent Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Etzer Darout | BMO Capital | $134.00 | $69.99 | 91.46% | 71.18% |
| Oct 24, 2024 | David Dai | UBS | $100.00 | $93.71 | 6.71% | 27.75% |
| Sep 16, 2024 | Kelsey Goodwin | Guggenheim | $105.00 | $110.25 | -4.76% | 34.13% |
| Sep 16, 2024 | Bradley Canino | Stifel Nicolaus | $135.00 | $87.45 | 54.37% | 72.46% |
| Sep 16, 2024 | Christopher Raymond | Raymond James | $100.00 | $87.45 | 14.35% | 27.75% |
| Jul 10, 2024 | Bradley Canino | Stifel Nicolaus | $115.00 | $73.63 | 56.19% | 46.91% |
| Apr 17, 2024 | Roger Song | Jefferies | $97.00 | $64.75 | 49.81% | 23.91% |
| Apr 01, 2024 | Christopher Liu | Leerink Partners | $110.00 | $75.09 | 46.49% | 40.52% |
The latest Nuvalent stock forecast, released on Nov 13, 2024 by Etzer Darout from BMO Capital, set a price target of $134.00, which represents a 91.46% increase from the stock price at the time of the forecast ($69.99), and a 71.18% increase from NUVL last price ($78.28).
Nuvalent Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $117.00 | $112.00 |
| Last Closing Price | $78.28 | $78.28 | $78.28 |
| Upside/Downside | -100.00% | 49.46% | 43.08% |
In the current month, the average price target of Nuvalent stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nuvalent's last price of $78.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 24, 2024 | UBS | Neutral | Initialise | |
| Sep 16, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | Wedbush | Outperform | Outperform | Hold |
| Sep 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 16, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 29, 2024 | Barclays | Overweight | Initialise | |
| Apr 17, 2024 | Jefferies | Buy | Initialise | |
| Apr 01, 2024 | Leerink Partners | Outperform | Upgrade | |
| Aug 08, 2023 | SVB Leerink | Outperform | Initialise |
Nuvalent's last stock rating was published by BMO Capital on Nov 13, 2024. The company gave NUVL a "Outperform" rating, the same as its previous rate.
Nuvalent Financial Forecast
Nuvalent Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $9.38M | $666.67K | - | - | - | - | - |
| High Forecast | $9.38M | $666.67K | - | - | - | - | - |
| Low Forecast | $9.38M | $666.67K | - | - | - | - | - |
| # Analysts | 1 | 1 | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NUVL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nuvalent EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NUVL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nuvalent's previous annual EBITDA (undefined) of $NaN.
Nuvalent Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-73.82M | $-76.47M | $-72.24M | $-68.20M | $-70.98M | $-61.35M | $-49.30M |
| High Forecast | $-73.82M | $-76.47M | $-72.24M | $-66.16M | $-62.71M | $-61.35M | $-49.30M |
| Low Forecast | $-73.82M | $-76.47M | $-72.24M | $-74.34M | $-88.21M | $-61.35M | $-49.30M |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NUVL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nuvalent SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nuvalent's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NUVL last annual SG&A of $NaN (undefined).
Nuvalent EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-1.12 | $-1.16 | $-1.10 | $-1.04 | $-1.08 | $-0.93 | $-0.76 |
| High Forecast | $-1.12 | $-1.16 | $-1.10 | $-1.01 | $-0.95 | $-0.93 | $-0.76 |
| Low Forecast | $-1.12 | $-1.16 | $-1.10 | $-1.13 | $-1.34 | $-0.93 | $-0.76 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Nuvalent's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NUVL previous annual EPS of $NaN (undefined).
Nuvalent Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.19 | $33.86 | 1446.12% | Buy |
| GPCR | Structure Therapeutics | $27.12 | $99.00 | 265.04% | Buy |
| CGEM | Cullinan Oncology | $12.18 | $34.00 | 179.15% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $19.78 | $37.50 | 89.59% | Buy |
| PCVX | Vaxcyte | $81.86 | $148.80 | 81.77% | Buy |
| REPL | Replimune Group | $12.11 | $19.00 | 56.90% | Buy |
| ASND | Ascendis Pharma | $137.67 | $211.14 | 53.37% | Buy |
| NUVL | Nuvalent | $78.28 | $114.80 | 46.65% | Buy |
| ACLX | Arcellx | $76.69 | $111.60 | 45.52% | Buy |
| TVTX | Travere Therapeutics | $17.42 | $21.75 | 24.86% | Buy |
| UTHR | United Therapeutics | $352.84 | $440.40 | 24.82% | Buy |
| VRDN | Viridian Therapeutics | $19.17 | $22.75 | 18.68% | Buy |